Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498927 · ClinicalTrials.gov registry record · Phase 2
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00498927: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00498927 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00498927, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent glioblastoma multiforme or other malignant glioma.
Interventions
- GENETIC protein expression analysis
- DRUG temozolomide
- OTHER diagnostic laboratory biomarker analysis
- OTHER immunoenzyme technique
- GENETIC reverse transcriptase-polymerase chain reaction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00498927
The ClinicalTrials.gov registry entry for NCT00498927 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00498927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00498927 about?
NCT00498927 is a clinical study titled "Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma". RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent glioblastoma...
What is the current status of trial NCT00498927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2007-06. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00498927?
The interventions under investigation include: protein expression analysis (GENETIC), temozolomide (DRUG), diagnostic laboratory biomarker analysis (OTHER), immunoenzyme technique (OTHER), reverse transcriptase-polymerase chain reaction (GENETIC).
Who is sponsoring clinical trial NCT00498927?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.